litlas
Log inCreate account

Ronald de Wit

Active 1988–2025

130
Papers
36,715
Citations
86
h-index
130
i10-index

Citations

Citations per year for Ronald de Wit1896: 2 citations1989: 2 citations1990: 3 citations1991: 5 citations1992: 3 citations1993: 2 citations1994: 2 citations1997: 4 citations1998: 10 citations1999: 9 citations2000: 13 citations2001: 24 citations2002: 24 citations2003: 35 citations2004: 56 citations2005: 116 citations2006: 116 citations2007: 110 citations2008: 164 citations2009: 168 citations2010: 193 citations2011: 159 citations2012: 170 citations2013: 304 citations2014: 250 citations2015: 254 citations2016: 282 citations2017: 270 citations2018: 338 citations2019: 1,076 citations2020: 1,222 citations2021: 1,253 citations2022: 927 citations2023: 628 citations2024: 1,054 citations2025: 447 citations2026: 8 citations1897–1988: no citations, so these years are not shown1995–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,229 citing papers, 24.5% of this breakdownChina: 973 citing papers, 7.4% of this breakdownUnited Kingdom: 924 citing papers, 7% of this breakdownItaly: 739 citing papers, 5.6% of this breakdownGermany: 730 citing papers, 5.5% of this breakdownCanada: 698 citing papers, 5.3% of this breakdownFrance: 648 citing papers, 4.9% of this breakdownNetherlands: 511 citing papers, 3.9% of this breakdownJapan: 491 citing papers, 3.7% of this breakdownSpain: 456 citing papers, 3.4% of this breakdownSwitzerland: 335 citing papers, 2.5% of this breakdownAustralia: 325 citing papers, 2.5% of this breakdown
0%24.5%Other 23.8%

Institutions

Fields

  • Medicine81.9%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Immunology and Microbiology2.9%
  • Engineering0.9%
  • Materials Science0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Other1.8%

Topics

  • Prostate Cancer Treatment and Research12.2%
  • Cancer Immunotherapy and Biomarkers7.6%
  • Bladder and Urothelial Cancer Treatments5.9%
  • Prostate Cancer Diagnosis and Treatment5.2%
  • Radiopharmaceutical Chemistry and Applications3.1%
  • Urinary and Genital Oncology Studies2.8%
  • Other63.2%

Coauthors

All papers

Open in search
  1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Authors: Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin - New England Journal of Medicine 2017 cited by 3,390

  2. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Authors: Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono - New England Journal of Medicine 2012 cited by 4,574

  3. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

    Authors: Ian F. Tannock, Ronald de Wit, William R. Berry, J Horti, A Płużańska, Kim N., Stéphane Oudard, Christine Théodore, Nicholas D. James, Ingela Turesson, Mark Rosenthal, Mario A. Eisenberger - New England Journal of Medicine 2004 cited by 5,725

  4. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

    Authors: Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Jeffrey C. Goh, Kristiina Ojamaa, Christopher Hoimes, Ulka N. Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko, Ronald de Wit, Chunde Li, Aurelius Omlin, Giuseppe Procopio, Satoshi Fukasawa, Ken-ichi Tabata, Se Hoon Park, Susan Feyerabend, Charles G. Drake, Haiyan Wu, Ping Qiu, Jeri Kim, Christian Poehlein, Johann S. de Bono - Journal of Clinical Oncology 2019 cited by 706

  5. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

    Authors: Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans, M. Roumiguié, Laurence E. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara L. Frenkl, Ronald de Wit - The Lancet Oncology 2021 cited by 533

  6. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    Authors: Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R. Plimack, Noah M. Hahn, Ronald de Wit, Lei Pang, Mary J. Savage, Rodolfo F. Perini, Stephen J. O’Keefe, Dean F. Bajorin, Joaquim Bellmunt - The Lancet Oncology 2017 cited by 1,342

  7. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

    Authors: Ronald de Wit, Johann S. de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean‐Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Daniel Castellano - New England Journal of Medicine 2019 cited by 660

  8. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    Authors: Yves Fradet, Joaquim Bellmunt, David J. Vaughn, J L Lee, Lawrence Fong, Nicholas J. Vogelzang, M.Á. Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, K. Nam, Tara L. Frenkl, Rodolfo F. Perini, Ronald de Wit, Dean F. Bajorin - Annals of Oncology 2019 cited by 488

  9. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

    Authors: Maria De Santis, Joaquim Bellmunt, Graham M. Mead, J. Martijn Kerst, Michael Leahy, Pablo Maroto, Thierry Gil, Sandrine Marréaud, Gedske Daugaard, Iwona Skoneczna, Sandra Collette, Julie Lorent, Ronald de Wit, Richard Sylvester - Journal of Clinical Oncology 2011 cited by 773

  10. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

    Authors: Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Savage, Xiao Fang, James Luke Godwin, Tara L. Frenkl, Blanca Homet Moreno, Ronald de Wit, Elizabeth R. Plimack - Journal of Clinical Oncology 2020 cited by 292

  11. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    Authors: Arjun Vasant Balar, Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Andrea Necchi, Daniel P. Petrylak, Elizabeth R. Plimack, Jin Xu, Kazuo Imai, Blanca Homet Moreno, Joaquim Bellmunt, Ronald de Wit, Peter H. O’Donnell - Annals of Oncology 2022 cited by 114

  12. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

    Authors: Lisanne F. van Dessel, Job van Riet, Minke Smits, Yanyun Zhu, Paul Hamberg, Michiel S. van der Heijden, Andries M. Bergman, Inge M. van Oort, Ronald de Wit, Emile E. Voest, Neeltje Steeghs, Takafumi N. Yamaguchi, Julie Livingstone, Paul C. Boutros, John W.M. Martens, Stefan Sleijfer, Edwin Cuppen, Wilbert Zwart, Harmen J.G. van de Werken, Niven Mehra, Martijn P. Lolkema - Nature Communications 2019 cited by 209

  13. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

    Authors: Silke Gillessen, Nicolas Sauvé, Laurence Collette, Gedske Daugaard, Ronald de Wit, Costantine Albany, A. Tryakin, Karim Fizazi, Olof Ståhl, Jourik A. Gietema, Ugo De Giorgi, Fay Cafferty, Aaron R. Hansen, Torgrim Tandstad, Robert Huddart, Andrea Necchi, Christopher J. Sweeney, Xavier García del Muro, Daniel Yick Chin Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R. Feldman, Angelika Terbuch, Marcus Hentrich, Carsten Bokemeyer, Helene F. S. Negaard, Christian D. Fankhauser, Jonathan Shamash, David J. Vaughn, Cora N. Sternberg, Axel Heidenreich, J. Beyer - Journal of Clinical Oncology 2021 cited by 238

  14. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

    Authors: Dominik Berthold, Gregory R. Pond, Freidele Soban, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock - Journal of Clinical Oncology 2008 cited by 1,145

  15. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

    Authors: Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Ugo De Giorgi, Michael Krainer, Andries M. Bergman, Wolfgang Hoelzer, Ronald de Wit, Martin Bögemann, Fred Saad, Giorgio Cruciani, Antoine Thiery-Vuillemin, Susan Feyerabend, Kurt Miller, Nadine Houédé, Syed A. Hussain, Elaine T. Lam, Jonathan Polikoff, Arnulf Stenzl, Paul N. Mainwaring, David A. Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi - Journal of Clinical Oncology 2016 cited by 247

  16. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

    Authors: Glenn Heller, Robert McCormack, Thian Kheoh, Arturo Molina, Matthew R. Smith, Robert Dreicer, Fred Saad, Ronald de Wit, Dana T. Aftab, Mohammad Hirmand, Ana Limon, Karim Fizazi, Martin Fleisher, Johann S. de Bono, Howard I. Scher - Journal of Clinical Oncology 2017 cited by 230

  17. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

    Authors: Andrea Necchi, M. Roumiguié, Ashish M. Kamat, Neal D. Shore, Joost L. Boormans, Adil Esen, Thierry Lebrét, Shuya Kandori, Dean F. Bajorin, Laurence E. Krieger, Scot A. Niglio, Edward Uchio, Ho Kyung Seo, Ronald de Wit, Eric A. Singer, Petros Grivas, Hiroyuki Nishiyama, Haojie Li, Pranshu Baranwal, Margot Van den Sigtenhorst-Fijlstra, Ekta Kapadia, Girish S. Kulkarni - The Lancet Oncology 2024 cited by 85

  18. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

    Authors: Cora N. Sternberg, Iwona Skoneczna, J. Martijn Kerst, Peter Albers, Sophie D. Fosså, Mads Agerbæk, Herlinde Dumez, Maria De Santis, Christine Théodore, Michael Leahy, John Chester, A. Verbaeys, Gedske Daugaard, Lori Wood, J. Alfred Witjes, Ronald de Wit, L. Geoffrois, Lisa Sengeløv, George N. Thalmann, Danielle Charpentier, Frédéric Rolland, L. Mignot, Santhanam Sundar, Paul Symonds, John D. Graham, Florence Joly, Sandrine Marréaud, Laurence Collette, Richard Sylvester - The Lancet Oncology 2014 cited by 387

  19. The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer

    Authors: Gregory R. Pond, Guru Sonpavde, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, Andrew J. Armstrong - European Urology 2013 cited by 198

  20. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

    Authors: J. Beyer, Laurence Collette, Nicolas Sauvé, Gedske Daugaard, Darren R. Feldman, Torgrim Tandstad, A. Tryakin, Olof Ståhl, Enrique González‐Billalabeitia, Ugo De Giorgi, Stéphane Culine, Ronald de Wit, Aaron R. Hansen, Marko Bebek, Angelika Terbuch, Costantine Albany, Marcus Hentrich, Jourik A. Gietema, Helene F. S. Negaard, Robert Huddart, Anja Lorch, Fay Cafferty, Daniel Yick Chin Heng, Christopher J. Sweeney, Eric Winquist, Michal Chovanec, Christian D. Fankhauser, Dan Stark, Peter Grimison, Andrea Necchi, Ben Tran, Axel Heidenreich, Jonathan Shamash, Cora N. Sternberg, David J. Vaughn, Ignacio Durán, Carsten Bokemeyer, Anna Patrikidou, Richard Cathomas, Samson Yaekob Assele, Silke Gillessen - Journal of Clinical Oncology 2021 cited by 171

  21. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells

    Authors: Lisanne Mout, Lisanne F. van Dessel, Jaco Kraan, Anouk C. de Jong, Rui P. Neves, Sigrun Erkens‐Schulze, Corine M. Beaufort, Anieta M. Sieuwerts, Job van Riet, Thomas Woo, Ronald de Wit, Stefan Sleijfer, Paul Hamberg, Yorick Sandberg, Peter A.W. te Boekhorst, Harmen J.G. van de Werken, John W.M. Martens, Nikolas H. Stoecklein, Wytske M. van Weerden, Martijn P. Lolkema - European Journal of Cancer 2021 cited by 92

  22. Cross-resistance and drug sequence in prostate cancer

    Authors: Stefan A.J. Buck, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ronald de Wit, Robert J. van Soest - Drug Resistance Updates 2021 cited by 82

  23. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    Authors: Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas - Clinical Cancer Research 2022 cited by 48

  24. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

    Authors: Felix E. de Jongh, Ruben N. van Veen, S J Veltman, Ronald de Wit, M.E.L. van der Burg, Martin J. van den Bent, A.S.T. Planting, Wilfried J. Graveland, G. Stoter, Jaap Verweij - British Journal of Cancer 2003 cited by 267